Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00439036
Other study ID # DA019436-01
Secondary ID R01DA019436-01DC
Status Completed
Phase Phase 1
First received February 21, 2007
Last updated May 3, 2013
Start date July 2006
Est. completion date December 2012

Study information

Verified date May 2013
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The purpose of this study is to develop an opiate detoxification behavior therapy based on current Acceptance and Commitment Therapy (ACT) theory and method, and to test its feasibility and promise in the context of voluntary methadone detoxification.


Description:

This Stage I pilot study will employ a randomized, controlled, between groups design in which 70 opiate dependent patients seeking methadone detoxification will be randomized into one of two treatment conditions: ACT opiate detoxification therapy or Drug Counseling. Both therapies will be delivered in the context of a 5-month methadone dose reduction based on a linear dosing strategy. Efficacy variables will include: (1) abstinence rates during and 1-month after detoxification as assessed by regular urine screens; (2) retention of patients in treatment; and (3) patient satisfaction and treatment acceptability. Reduction in HIV/Hepatitis C risk behaviors and changes in psychosocial functioning (e.g., employment, family, legal) will also be explored, along with mediators/moderators of the therapy (i.e., experiential avoidance). Subjects will be recruited from Houston area methadone clinics and the general community via advertising and will receive methadone as part of this protocol. A 2-4 week stabilization period will precede the 5-month methadone dose reduction. During the dose reduction, participants will attend the clinic twice each week and will receive weekly therapy. Participants will be contacted for follow up assessments up to one month post treatment.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date December 2012
Est. primary completion date August 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria:

- Ages 25 through 60

- Dependent upon opiates (heroin/methadone) according to DSM-IV criteria

- Using heroin/methadone for at least 5 years

- Endorse 7 or higher on a 10-point motivation for opiate detoxification item

- In good physical and psychiatric health

- Able to read, speak, and understand English

- Willing and able to meet study requirements

- Willing to participate in the 1 month follow up session

- Able to provide the name of at least one person who can generally locate them

- Attending a licensed methadone clinic regularly with opiate (other than methadone) negative urine screens in the past month.

- Intake screen negative for opiates (other than methadone)

- >110 lbs & body mass index between 18 and 28 kg/m2

Exclusion Criteria:

- Younger than 25 and older than 60 years of age

- Current dependence on other substances

- Severe medical, cognitive, and/or psychiatric impairment that precludes cooperation with study protocol

- Current and severe psychiatric symptoms requiring medical attention

- Current substance withdrawal symptoms requiring medical attention

- Unable to read, speak, and understand English

- Unwillingness of women of child bearing age to use contraception

- Currently receiving other psychosocial therapy for substance abuse (12-step meetings are ok)

- Impending incarceration

- Unable or unwilling to meet study requirements, including provision of signed consent

- Less than 7 on a 10-point motivation for opiate detoxification scale

- no documentation of monitored methadone use

- non-methadone opiate positive urine screen in the past month according to self-report

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Behavior Therapy
The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
Drug Counseling


Locations

Country Name City State
United States University of Texas Medical School- Houston; Department of Psychiatry; Mental Sciences Institute Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Substance use Baseline, twice a week, end of study, one month after the study, 6 months after the study No
Primary HIV/HCV risk behaviors Intake, week 9, week 19 No
Secondary Retention twice a week No
Secondary Client adherence twice a week No
Secondary Psychosocial functioning baseline and once a month No
Secondary Treatment satisfaction once a month No
See also
  Status Clinical Trial Phase
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Completed NCT01690546 - Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence Phase 2
Completed NCT01442493 - Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment N/A
Completed NCT01389167 - Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia Phase 3
Completed NCT01182402 - Electronic Compliance Monitoring in Opioid Substitution Treatment N/A
Completed NCT00634803 - Clinical Trial of Integrated Treatment for Pain and Opioid Dependence Phase 1/Phase 2
Completed NCT00987961 - Linking Hospitalized Injection Drug Users to Buprenorphine Phase 3
Completed NCT00757744 - Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China Phase 3
Completed NCT00539123 - Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia N/A
Completed NCT00577408 - Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Phase 3
Completed NCT00566969 - Cocaine Withdrawal and Pharmacotherapy Response N/A
Recruiting NCT00241930 - Integrating Buprenorphine Into HIV Treatment Phase 4
Completed NCT00218621 - The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1 Phase 2
Completed NCT00406484 - Brief Introductory Therapy for Opioid Dependence Phase 2
Completed NCT00580827 - Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers N/A
Completed NCT03015597 - Pilot Study of Contingency Management for Smoking Cessation N/A
Completed NCT01393392 - Developing a Smoking Cessation Intervention for Methadone Maintained Smokers Phase 1
Completed NCT01416584 - A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment N/A
Recruiting NCT00439049 - Substance Abuse Pre-Treatment Screening Study
Withdrawn NCT00398008 - HIV Risk Reduction and Drug Abuse Treatment in Iran Phase 2

External Links